sj-pdf-1-tan-10.1177_1756286420987941 – Supplemental material for Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination

Supplemental material, sj-pdf-1-tan-10.1177_1756286420987941 for Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination by Ludwig Kappos, Stanley Cohan, Douglas L. Arnold, Randy R. Robinson...

Full description

Bibliographic Details
Main Authors: Ludwig Kappos (253872), Stanley Cohan (3486812), Douglas L. Arnold (8832665), Randy R. Robinson (10209523), Joan Holman (5170199), Sami Fam (10209526), Becky Parks (8774170), Shan Xiao (3117867), Wanda Castro-Borrero (5339651)
Format: Other Non-Article Part of Journal/Newspaper
Language:unknown
Published: 2021
Subjects:
Neurology and Neuromuscular Diseases
Pharmacology and Pharmaceutical Sciences not elsewhere classified
autoimmunity
daclizumab
encephalitis
multiple sclerosis
sami
Online Access:https://doi.org/10.25384/sage.14131909.v1
Description
Summary:Supplemental material, sj-pdf-1-tan-10.1177_1756286420987941 for Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination by Ludwig Kappos, Stanley Cohan, Douglas L. Arnold, Randy R. Robinson, Joan Holman, Sami Fam, Becky Parks, Shan Xiao and Wanda Castro-Borrero in Therapeutic Advances in Neurological Disorders

Similar Items